ArticleBMC research notes2025
Investigating the effect of Ranolazine drug on the pathophysiology of asthma in a rat model.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAsthma is a common multifactorial inflammatory disease affecting both children and adults. Various cells and cytokines contribute to this inflammatory process. Smooth muscle contraction, vascular congestion, and airway edema lead to airway narrowing, which is an important factor in asthma. This study explores the potential impact of Ranolazine, a sodium blocker used for chronic angina, on asthmatic rats. By investigating the drug's effects on vascular and lung tissue changes, this research seeks to offer perspectives on innovative treatment approaches for asthma.
resultsRanolazine treatment showed minimal impact on serum IgE levels in asthmatic rats, with a slight reduction that was statistically insignificant. However, Ranolazine treatment resulted in a significant decrease in perivascular and peribronchial inflammation levels compared to the asthmatic group, suggesting a potential therapeutic effect on lung histology changes associated with asthma pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.